CRANBURY, N.J., Aug. 4, 2023
/PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a
biopharmaceutical company developing first-in-class medicines based
on molecules that modulate the activity of the melanocortin
receptor system, today announced that management will participate
at the Canaccord Genuity 43rd Annual Growth Conference
on Wednesday, August 9, 2023 at
5:00 p.m. ET in an Analyst led
Fireside Chat.
A live webcast of the Fireside Chat will be available on the
Investors section of Palatin's website at http://www.palatin.com. A
replay of the webcast will be available for 30 days following the
presentation.
About Palatin
Palatin is a biopharmaceutical company developing first-in-class
medicines based on molecules that modulate the activity of the
melanocortin receptor systems, with targeted, receptor-specific
product candidates for the treatment of diseases with significant
unmet medical need and commercial potential. Palatin's strategy is
to develop products and then form marketing collaborations with
industry leaders to maximize their commercial potential. For
additional information regarding Palatin, please visit Palatin's
website at www.palatin.com and follow Palatin on Twitter
at @PalatinTech.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/palatin-to-participate-in-canaccord-genuitys-43rd-annual-growth-conference-301893395.html
SOURCE Palatin Technologies, Inc.